Product Name: Trofinetide
Form: Free base
CAS No: 853400-76-7
Molar Mass: 315.32
Chemical Formula: C13H21N3O6
Synonyms: NNZ-2566
Storage: Store at -20℃
Sequence: GXE
Application:
Trofinetide (CAS: 853400-76-7) is a synthetic peptide drug currently under investigation for the treatment of Rett syndrome, a rare neurodevelopmental disorder primarily affecting females. It functions by modulating the activity of the neurotrophic factor insulin-like growth factor 1 (IGF-1) and the neuropeptide oxytocin, both of which play important roles in brain development and function. Trofinetide is believed to enhance synaptic connectivity, neuroplasticity, and neurotransmitter balance in the brain, potentially leading to improvements in cognitive, motor, and behavioral symptoms associated with Rett syndrome. In pharmaceutical chemistry, trofinetide's targeted mechanisms of action represent a promising approach to addressing the underlying pathophysiology of Rett syndrome, offering hope for improved outcomes and quality of life for individuals affected by this devastating condition. Ongoing clinical trials aim to further evaluate trofinetide's safety and efficacy, with the goal of ultimately providing a much-needed treatment option for Rett syndrome patients and their families.
Current Research:
Trofinetide is a synthetic analog of the naturally occurring peptide, Gly-Pro, and is primarily investigated for its potential in treating neurodevelopmental disorders, particularly Rett syndrome. Rett syndrome is a rare genetic disorder that primarily affects females and leads to severe cognitive and motor impairments. Trofinetide acts by targeting and modulating the glutamatergic system, playing a role in synaptic plasticity and neuronal communication. Its mechanism of action is thought to involve the enhancement of neurotrophic factor signaling and the modulation of the mTOR (mechanistic target of rapamycin) pathway, which is essential for neuronal growth and synaptic function. Trofinetide has shown promise in clinical trials as a therapeutic approach to improving functional outcomes in patients with Rett syndrome.
Mechanism of Action
Trofinetide works through its action as an analog of the dipeptide Gly-Pro, a component that influences neurotrophic factor signaling. It is believed to help restore synaptic function and improve neuronal communication, which is disrupted in conditions like Rett syndrome. By enhancing the signaling pathways involved in synaptic plasticity, Trofinetide may promote neuronal repair and functional recovery. Additionally, it may modulate the mTOR signaling pathway, which plays a critical role in cell growth, survival, and synaptic strength, providing neuroprotective effects and improving cognitive and motor functions. This mechanism distinguishes Trofinetide from other treatments for Rett syndrome by targeting both the molecular and cellular dysfunctions seen in the disease.
Indications and Uses
Trofinetide is being investigated as a treatment for Rett syndrome, a rare genetic disorder that predominantly affects females and is characterized by a period of normal development followed by a loss of motor skills, speech, and social engagement. The drug has demonstrated potential in improving clinical outcomes in patients with Rett syndrome, including better motor abilities, communication skills, and overall functioning. It is being developed as an oral therapy for patients with moderate to severe forms of Rett syndrome, with the aim of providing a novel treatment that addresses the underlying neurodevelopmental aspects of the disorder rather than just managing symptoms.
Efficacy and Clinical Benefits
Clinical trials have shown that Trofinetide can improve several key symptoms of Rett syndrome, particularly in the areas of motor function and social interaction. In a phase 2 clinical trial, patients receiving Trofinetide showed significant improvements in measures of social engagement, motor skills, and language development compared to those receiving a placebo. These results indicate that Trofinetide may not only help alleviate some of the functional impairments associated with Rett syndrome but also help enhance overall quality of life for affected individuals. The drug is considered a promising therapeutic option, especially for those patients who have limited treatment alternatives, as current options primarily focus on symptom management rather than addressing the root causes of the disease.
Safety and Tolerability
Trofinetide has shown a favorable safety and tolerability profile in clinical trials, with most side effects being mild to moderate in nature. The most commonly reported side effects include gastrointestinal issues such as nausea, diarrhea, and decreased appetite. Some patients also experience mild headaches and fatigue. These side effects are generally transient and manageable, with no significant concerns related to the drug’s long-term safety. Unlike many neurodevelopmental disorder treatments, Trofinetide does not carry the risk of severe neurological or psychiatric side effects, which is a significant advantage for patients requiring long-term treatment. Regular monitoring is still recommended, especially for gastrointestinal symptoms, to ensure that patients remain comfortable during treatment.
Advantages and Limitations
Trofinetide’s main advantage is its potential to address the underlying neurodevelopmental dysfunction in Rett syndrome, rather than simply managing symptoms. It provides a novel treatment approach by targeting molecular pathways involved in synaptic function and plasticity, offering hope for improved outcomes in patients with Rett syndrome. Additionally, its oral administration makes it more convenient compared to other treatments that may require injections or more invasive methods. However, its use is currently limited to patients with Rett syndrome, and more research is needed to establish its safety and efficacy in other neurodevelopmental disorders. Its relatively new status in clinical development means that further long-term data is required to confirm its broader applicability and benefit.
Future Directions
Ongoing clinical trials are evaluating the long-term safety and efficacy of Trofinetide in treating Rett syndrome and other related neurodevelopmental conditions. Research is also focusing on identifying potential biomarkers that could predict patient response to treatment, optimizing dosing regimens, and exploring the combination of Trofinetide with other therapeutic strategies. The ongoing exploration of Trofinetide’s potential in other neurodevelopmental disorders, such as autism spectrum disorder or fragile X syndrome, is also an exciting area of development. As more data becomes available, Trofinetide may become a key component in the therapeutic arsenal for managing neurodevelopmental diseases.
Reference:
Get a Quote
LinkPeptide
